First human test of CAR-T therapy targets tough digestive cancers

NCT ID NCT06197178

Summary

This early-stage study tested a new type of personalized immune cell therapy called LCAR-G08 in 17 adults with advanced cancers of the digestive system (like colorectal or stomach cancer). The main goals were to find the safest dose and see how well the body handled the treatment. Researchers also checked if the therapy could help shrink the participants' tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTROINTESTINAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Cancer Hospital & Institute

    Beijing, Beijing Municipality, 100142, China

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, 102200, China

Conditions

Explore the condition pages connected to this study.